Scarica l'app Stockscreener
41.44
3.03%
1.22
Precedente Chiudi:
$40.22
Aprire:
$40.51
Volume 24 ore:
3.38M
Relative Volume:
1.17
Capitalizzazione di mercato:
$5.33B
Reddito:
$10.12M
Utile/perdita netta:
$-280.49M
Rapporto P/E:
-14.34
EPS:
-2.89
Flusso di cassa netto:
$-188.51M
1 W Prestazione:
-11.11%
1M Prestazione:
-10.82%
6M Prestazione:
+33.20%
1 anno Prestazione:
-0.74%
Intervallo 1D:
$40.31
$41.88
Intervallo di 1 settimana:
$35.70
$49.16
Portata 52W:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
41.44 | 5.17B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.36 | 100.82B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
461.24 | 60.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.06 | 60.69B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
752.32 | 46.32B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
327.20 | 36.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Avidity Biosciences (NASDAQ:RNA) Trading Down 5.3%Here's What Happened - MarketBeat
Bank of America Issues Positive Forecast for Avidity Biosciences (NASDAQ:RNA) Stock Price - MarketBeat
Ark, Atom file to go public in Hong Kong; Aptevo’s stock rallies on AML data - Endpoints News
MACD Signal: Is Avidity Biosciences Inc part of any major index2025 Trading Recap & AI Based Trade Execution Alerts - خودرو بانک
Avidity Biosciences prices $600M stock offering - MSN
Will Avidity Biosciences Inc announce a stock splitJuly 2025 Movers & Low Risk High Reward Trade Ideas - خودرو بانک
Trading Recap: What is the dividend yield of USGOW2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - خودرو بانک
Volume Report: How does Avidity Biosciences Inc compare to its peersIPO Watch & Verified Chart Pattern Trade Signals - خودرو بانک
Dow Update: What is Avidity Biosciences Incs book value per shareEarnings Risk Report & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Avidity Biosciences closes $690 million public offering By Investing.com - Investing.com Canada
Avidity Biosciences, Inc. Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - StreetInsider
Avidity Biosciences closes $690 million public offering - Investing.com
Avidity Biosciences Closes $690 Million Share Offering - MarketScreener
Volume Summary: Can Avidity Biosciences Inc outperform in the next rallyJuly 2025 Catalysts & Safe Entry Zone Tips - خودرو بانک
Avidity Biosciences stock price target raised to $87 by H.C. Wainwright - Investing.com Canada
Moving Averages: Is Avidity Biosciences Inc part of any major index2025 Earnings Surprises & High Return Trade Guides - خودرو بانک
Institution Moves: Can Avidity Biosciences Inc outperform in the next rallyLayoff News & Free Safe Capital Growth Stock Tips - خودرو بانک
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Profit Review: Is Avidity Biosciences Inc. trading at a discount2025 AllTime Highs & Verified High Yield Trade Plans - خودرو بانک
Rhumbline Advisers Has $4.86 Million Stock Position in Avidity Biosciences, Inc. $RNA - MarketBeat
Insider Selling: Avidity Biosciences (NASDAQ:RNA) Director Sells 29,500 Shares of Stock - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Shares Gap Up on Analyst Upgrade - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Given New $87.00 Price Target at HC Wainwright - MarketBeat
Avidity Biosciences Announces Major Stock Offering - MSN
Avidity Biosciences (NASDAQ:RNA) Shares Gap DownWhat's Next? - MarketBeat
Avidity Biosciences (RNA) Gets 9% Boost from Higher PT, Rating - Yahoo Finance
Avidity Biosciences (RNA) Is Down 11.2% After $600 Million Equity Raise to Fund Late-Stage Pipeline - Yahoo Finance
Avidity Biosciences launches $500M proposed public offering - MSN
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering - Wilson Sonsini
Avidity Biosciences files for offering of 15 million shares of common stockSEC filing - MarketScreener
Avidity Biosciences stock price target raised to $65 at BofA Securities - Investing.com Australia
Latham & Watkins Advises Avidity Biosciences on Upsized US$600 Million Public Offering of Common Stock - Latham & Watkins LLP
Avidity Biosciences (NASDAQ:RNA) Price Target Raised to $65.00 at Needham & Company LLC - MarketBeat
Avidity Biosciences' (RNA) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Avidity’s offering follows reversal of Duchenne disease progression - BioWorld MedTech
A new biotech fund in the Middle East; Xspray preps for FDA decision on Dasynoc - Endpoints News
HC Wainwright Adjusts Avidity Biosciences Price Target to $87 From $68, Maintains Buy Rating - MarketScreener
Avidity Biosciences reports data from DMD treatment trials - MSN
Avidity Biosciences price target raised to $87 from $68 at H.C. Wainwright - TipRanks
Avidity Biosciences Prices $600 Million Equity Offering - MarketScreener
Avidity Biosciences prices upsized public offering at $600 million By Investing.com - Investing.com South Africa
Avidity Biosciences prices upsized public offering at $600 million - Investing.com India
Alyeska Investment Group L.P. Has $2.95 Million Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences prices upsized public offering at $40 per share - MarketScreener
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - Nasdaq
Share Sales Send Small Biotech Stocks To New Lows - Finimize
Avidity Biosciences: Maintaining 'Strong Buy' Rating Based On Accelerated Approval Filing For Del-Zota - Seeking Alpha
Top Midday Decliners - MarketScreener
Avidity Biosciences: Promising Outlook for DMD Treatment with Del-Zota and Platform Expansion - TipRanks
A Quick Look at Today's Ratings for Avidity Biosciences(RNA.US), With a Forecast Between $56 to $96 - 富途牛牛
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA - BioSpace
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.77%
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):